Bioactive O^N^O^ Schiff base appended homoleptic titanium(iv) complexes: DFT, BSA/CT-DNA interactions, molecular docking and antitumor activity against HeLa and A549 cell lines

Five new homoleptic derivatives of titanium(iv) have been developed and characterized by physicochemical techniques. Metal complexes, TiH2L1 [(C38H26N6O4)Ti], TiH2L2 [(C38H24F2N6O4)Ti], TiH2L3 [(C38H24Cl2N6O4)Ti], TiH2L4 [(C38H24Br2N6O4)Ti] and TiH2L5 [(C38H24N8O8)Ti], were obtained by treating Ti(OPri)4 with appropriate ONO ligands (H2L1-H2L5) in anhydrous THF as solvent. The electronic structures and properties of titanium(iv) complexes (TiH2L1-TiH2L5) and ligands (H2L1-H2L5) were examined by DFT studies. The stability of all synthesized derivatives was assessed by a UV-visible technique using 10% DMSO, GSH medium and n-octanol/water systems. The binding interactions of BSA and CT-DNA with respective titanium(iv) complexes were successfully evaluated by employing UV-visible absorption, fluorescence, circular dichroism (CD) techniques and docking studies. The in vitro cytotoxicity of TiH2L2, TiH2L3 and TiH2L4 complexes was assessed against HeLa (human epithelioid cervical cancer cells) and A549 (lung carcinoma) cell lines. The IC50 values of TiH2L2, TiH2L3 and TiH2L4 were observed to be 28.8, 14.7 and 31.2 μg mL-1 for the HeLa cell line and 38.2, 32.9 and 67.78 μg mL-1 for A549 cells, respectively. Complex TiH2L3 exhibited remarkably induced cell cycle arrest in the G1 phase and 77.99% ROS production selectivity in the HeLa cell line.

Hydrolytically Stable TiIV-Hydrazone-Based Metallodrugs: Protein Interaction and Anticancer Potential

In this work, three titanium(IV) [TiIV(L1-3)2] (1-3) complexes have been reported using three different tridentate dibasic ONO donor hydrazone ligands, pyridine-4-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)-hydrazide (H2L1), furan-2-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)-hydrazide (H2L2), and thiophene-2-carboxylic acid (3-ethoxy-2-hydroxybenzylidene)-hydrazide (H2L3) tethered with heterocyclic moieties. Elemental analysis, FT-IR, UV-vis, NMR, HR-ESI-MS, and single-crystal X-ray analysis have been used to characterize H2L1-3 and 1-3. In solid structures of 1-3, two ligand molecules with N2O4 donor sets give distorted octahedral geometries to the metal center. The aqueous stability of 1-3 was investigated and well correlated to their perceived pharmacological results. During the investigation, all three complexes were found to be hydrolytically stable in a 90% DMSO-d6/10% D2O (v/v) medium up to 48 h. Furthermore, the interaction of 1-3 with bovine serum albumin (BSA) was tested using fluorescence and absorption techniques. The complexes showed static quenching with a biomolecular quenching constant of Kq ∼ 1013 proposing a high affinity of complexes for BSA. Finally, the anticancer potential of 1-3 was tested against HeLa, A549, and NIH-3T3 cell lines. Among all, 1 with an IC50 value of 11.6 ± 1.1 μM against HeLa cells was found to be the most cytotoxic in the series. Furthermore, it has been found that the compounds induce an apoptotic mode of cell death, which is confirmed by the live cell confocal microscopy and flow cytometry techniques.

Niobium Complexes Supported by Chalcogen-Bridged [OEO]-Type Bis(phenolate) Ligands (E = S, Se): Synthesis, Characterization, and Phenylacetylene Polymerization

Trichloro niobium(V) complexes 3 and 4 with the sulfur- or selenium-bridged [OEO]-type bis(phenolate) ligands (E = S, Se) were synthesized and fully characterized on the basis of their NMR spectroscopic data and X-ray crystallographic analysis. In the crystalline state of 4, the [OSeO]-core of the ligand was coordinated to the niobium center in a fac-fashion. The corresponding tribenzyl niobium(V) complexes 5 and 6 were also prepared by the reactions of 3 and 4 with 3 equivalents of PhCH2MgCl in toluene. The X-ray diffraction analysis of 6 revealed that the distorted six-coordinated niobium center incorporated in the [OSeO]-type ligand took a mer-fashion, and one benzyl ligand was coordinated to the niobium center by η2-fashion. Complexes 5 and 6 were tested for the phenylacetylene polymerization that produced poly(phenylacetylene)s (PPAs), oligomers, and triphenylbenzenes (TPBs) depending on the chalcogen atom in the [OEO]-type ligand.

Synthesis and X-ray structure analysis of cytotoxic heptacoordinated Salan hafnium(IV) complexes stabilized with 2,6-dipicolinic acid

Four novel Salan Hf^(IV) complexes stabilized by 2,6-dipicolinic acid (Dipic) were synthesized and characterized by ¹H, ¹³C NMR and X-ray diffraction spectroscopy. These Hf^(IV)bis-chelates could be obtained in good to excellent yields (88%-91%) and demonstrated rather good stability in aqueous media and on silica gel. [L₂Hf^(IV)Dipic^4-H,Cl] containing steric bulk L₂ were stable in about 10% H₂O (H₂O/THF (v/v)), however, [L₁Hf^(IV)Dipic^4-H,Cl] with non-steric L₁ could slowly dissociate and release nontoxic L₁. [L_1-2Hf^(IV)Dipic^4-Cl] showed excellent anti-tumoral activity in the range of cisplatin (Hela S3: IC₅₀ = 3.5 ± 0.4 μM, Hep G2: IC₅₀ = 11.2 ± 2.1 μM). In addition, the cellular uptake and apoptosis investigation of [L₁Hf^(IV)Dipic^4-Cl] suggested a fast cellular uptake process against Hela S3 cells with an almost exclusive induced apoptosis cell death path.

Facile synthesis of [ONON] type titanium(IV)bis-chelated complexes in alcoholic solvents and evaluation of anti-tumor activity

Novel anti-tumoral diamino-bis-(phenolato) [ONON] type titanium^(IV) complexes stabilized by 2,6-dipicolinic acid were synthesis via an efficient protocol using n-propanol as solvent and H₂O for isolation. In total 20 [ONON] type and 2 Salan Ti^(IV)bis-chelated complexes were synthesized with yields ranging from 68% to 96%. All reactions could reach to completion in 1.5 min at 80 °C either using Ti(OⁱPr)₄ or TiCl₄ as starting materials. Most [ONON] type Ti^(IV) complexes exhibit selectively enhanced inhibition activity against Hep G2 cells in comparison with Salan Ti^(IV) complexes. Among which, the inhibitory activity of 2 t (IC₅₀: 0.15 ± 0.1 μM) against Hep G2 cells is about 80 times enhanced than that of cisplatin (IC₅₀: 12.4 ± 1.2 μM). The [ONON] type Ti^(IV) complexes slowly released nontoxic phenolato ligands in presence of large amount of aqueous media, and a fast cellular uptake process was proposed for these Ti^(IV) complexes based on metal uptake analysis. Decagram scale synthesis indicates this facile synthetic methodology can be applied to large scale synthesis.

New titanocene derivative with improved stability and binding ability to albumin exhibits high anticancer activity

Titanium-based therapies have emerged as a promising alternative for the treatment of cancer patients, particularly those with cisplatin resistant tumors. Unfortunately, some titanium compounds show stability and solubility problems that have hindered their use in clinical practice. Here, we designed and synthesized a new titanium complex containing a titanocene fragment, a tridentate ligand to improve its stability in water, and a long aliphatic chain, designed to facilitate a non-covalent interaction with albumin, the most abundant protein in human serum. The stability and human serum albumin affinity of the resulting titanium complex was investigated by UV-Vis absorption and fluorescence spectroscopy techniques. Complex [TiCp₂{(OOC)₂py-O-myr}] (3) (myr = C₁₄H₂₉, py = pyridine) and its analogous [TiCp₂{(OOC)₂py-OH}] (4), lacking the aliphatic chain, showed improved stability in phosphate saline buffer compared with [TiCp₂Cl₂] (1). 3 showed a strong interaction with human serum albumin in a 1:1 stoichiometry. The cytotoxic effect of 3 was higher compared to [TiCp₂Cl₂] in tumor cell lines and showed potential tumor selectivity when assayed in non-tumor human epithelial cells. Finally, 3 showed an antiproliferative effect on cancer cells, decreasing the population in the S phase, and increasing apoptotic cells in a significant manner. All this makes the novel Ti(IV) compound 3 a firm candidate to continue further studies of its therapeutic potential in vitro and in vivo.